Dojolvi

Chemical Nametriheptanoin
Dosage FormLiquid (oral; 100% w/w of triheptanoin)
Drug ClassMiscellaneous
SystemDigestive
CompanyUltragenyx Pharm Inc
Approval Year2020

Indication

  • Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Dojolvi (triheptanoin) Prescribing Information.2020Ultragenyx Pharmaceutical Inc., Novato, CA